Published in Cancer Weekly, January 3rd, 2006
In September 2004 the companies entered into a collaboration to discover and develop small molecule cancer therapeutics targeting kinases, a family of cell signaling enzymes that play a major role in the progression of cancer.
The milestone payment was triggered by identifying compounds with specific predetermined pre-clinical characteristics.
Sunesis is working to produce small molecule therapeutics...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly